SG Americas Securities LLC Acquires 5,078 Shares of Fresenius Medical Care AG (NYSE:FMS)

SG Americas Securities LLC increased its holdings in Fresenius Medical Care AG (NYSE:FMS – Free Report) by 50.0% during the first quarter, according to its most recent filing with the SEC. The company owned 15,228 shares of the company’s stock after purchasing an additional 5,078 shares during the period. SG Americas Securities LLC’s stock in Fresenius Medical Care was worth $294,000 at the end of the most recent reporting period.

Several other large investors also modified their holdings in the company. Hartford Financial Management Inc. increased its stake in Fresenius Medical Care by 98.8% in the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock worth $35,000 after acquiring an additional 839 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Fresenius Medical Care by 349.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock worth $48,000 after acquiring an additional 1,799 shares during the period. GAMMA Investing LLC purchased a new stake in shares of Fresenius Medical Care in the fourth quarter worth $67,000. Assetmark Inc. increased its position in Fresenius Medical Care by 169.9% in the fourth quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after purchasing an additional 2,630 shares in the last quarter. Finally, ORG Partners LLC bought a new position in Fresenius Medical Care in the first quarter worth about $110,000. Institutional investors own 8.25% of the company’s shares.

Fresenius Medical Care stock return

Shares of FMS opened at $19.61 on Tuesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.14 and a current ratio of 1.50. The stock has a 50-day moving average of $20.38 and a 200-day moving average of $20.04. The stock has a market cap of $11.51 billion, a price/earnings ratio of 22.03, a price/earnings/growth ratio of 1.05 and a beta of 0.90. Fresenius Medical Care AG has a one-year low of $16.37 and a one-year high of $26.99.

Fresenius Medical Care (NYSE:FMS – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.10. The company had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. As a group, research analysts predict that Fresenius Medical Care AG will post 1.5 EPS for the current year.

Wall Street analysts predict growth

FMS has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Wednesday, July 3rd. They gave the stock a “strong-buy” rating. Truist Financial raised their price target on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has given the company a strong buy rating. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $32.25.

Read our latest report on Fresenius Medical Care

Company Profile Fresenius Medical Care

(Free Report)

Fresenius Medical Care AG provides dialysis and related services for individuals with kidney disease in Germany, North America and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; supplies, training and patient support services consisting of clinical monitoring, follow-up assistance and arranging for delivery of supplies to the patient’s home; and contract dialysis services to hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients suffering from acute renal failure.

Featured Stories

Receive daily news and reviews for Fresenius Medical Care – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Fresenius Medical Care and related companies with MarketBeat.com’s FREE daily email newsletter.